Adalimumab Export Market Intelligence: India's 67 Suppliers Shipping to 53 Countries — TransData Nexus 2026

Q: Who are the top adalimumab exporters from India?

The top adalimumab exporters from India are: 1. RELIANCE LIFE SCIENCES PRIVATE LIMITED — $338.1K (28.3% market share); 2. ZYDUS LIFESCIENCES LIMITED — $66.8K (5.6% market share); 3. CADILA HEALTHCARE LIMITED — $37.5K (3.1% market share); 4. PHARMA CHOICE LLP — $26.7K (2.2% market share); 5. REMEDI PHARMA DISTRIBUTORS — $25.4K (2.1% market share). Together they account for 41.5% of India's total adalimumab export value.

Q: What is the total export value of adalimumab from India?

The total export value of adalimumab from India is $1.2M USD, recorded across 223 shipment transactions from 67 active exporters to 53 destination countries. The average shipment value is $5.3K.

Q: Which countries import adalimumab from India?

India exports adalimumab to 53 countries worldwide. The top importing countries are: VENEZUELA (27.9% share, $332.6K), SRI LANKA (20.0% share, $238.3K), NEPAL (10.9% share, $130.3K), BANGLADESH (9.9% share, $117.6K), UNITED ARAB EMIRATES (6.6% share, $78.9K). These five markets account for 75.3% of total export value.

Q: What is the HS code for adalimumab exports from India?

The primary HS code for adalimumab exports from India is 30021500. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of adalimumab exports from India?

The average unit price for adalimumab exports from India is $111.11 USD per unit, with prices ranging from $0.98 to $1245.35 depending on formulation, packaging, and order volume. The total market is valued at $1.2M across 223 shipments.

Q: Which ports handle adalimumab exports from India?

The primary ports for adalimumab exports from India are SAHAR AIR (24.7% of shipments), SAHAR AIR CARGO ACC (INBOM4) (21.1% of shipments), DELHI AIR CARGO ACC (INDEL4) (10.3% of shipments), Bombay Air (7.6% of shipments), DELHI AIR (4.9% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of adalimumab?

India is one of the world's leading exporters of adalimumab due to its large base of 67 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports adalimumab to 53 countries, demonstrating 27% global market coverage.

Q: What certifications do Indian adalimumab exporters need?

Indian adalimumab exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import adalimumab from India?

There are 97 registered buyers importing adalimumab from India, spread across 53 countries. The repeat buyer rate is 48.5%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top adalimumab supplier from India?

RELIANCE LIFE SCIENCES PRIVATE LIMITED is the leading adalimumab exporter from India with a market share of 28.3% and total export value of $338.1K across 20 shipments. The top 5 suppliers together control 41.5% of total export value.

Suresh Sormare

Adalimumab

India Pharmaceutical Trade Intelligence

$1.2M67 Suppliers53 CountriesHS 30021500

ExportsIndia → VENEZUELA27.9%India → SRI LANKA20.0%

ImportsUNITED STATES → India$167.7K UNITED KINGDOM → India$28.5K

#1 Supplier: RELIANCE LIFE

Adalimumab Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Adalimumab to the World

Between 2022 and 2026, India exported $1.2M worth of adalimumab across 223 verified shipments to 53 countries — covering 27% of world markets in the Biologics & Immunotherapy segment. The largest destination is VENEZUELA (27.9%). RELIANCE LIFE SCIENCES PRIVATE LIMITED leads with a 28.3% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Adalimumab export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Adalimumab export data snapshot — $1.2M · 67 exporters · 53 countriesTransData Nexus · Indian Customs Data

Top Adalimumab Exporters from India

67 active exporters · Ranked by export value

View all 67 →

Top Adalimumab Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	RELIANCE LIFE SCIENCES PRIVATE LIMITED	$338.1K	20	10	28.3%
2	ZYDUS LIFESCIENCES LIMITED

Top Countries Importing Adalimumab from India

53 destination markets · Ranked by import value

All 53 countries →

Top Countries Importing Adalimumab from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	VENEZUELA	$332.6K	27.9%
2	SRI LANKA	$238.3K	20.0%
3	NEPAL	$130.3K	10.9%
4	BANGLADESH	$117.6K	9.9%
5	UNITED ARAB EMIRATES	$78.9K	6.6%
6	LEBANON	$59.7K	5.0%
7	UNITED STATES	$26.4K	2.2%
8	MAURITIUS	$19.5K	1.6%
9	NIGERIA	$17.6K	1.5%
10	MALDIVES	$14.1K	1.2%

VENEZUELA is India's largest adalimumab export destination, absorbing 27.9% of total exports worth $332.6K. The top 5 importing countries — VENEZUELA, SRI LANKA, NEPAL, BANGLADESH, UNITED ARAB EMIRATES — together account for 75.3% of India's total adalimumab export value. The remaining 48 destination countries collectively receive the other 24.7%, indicating a broadly diversified export footprint across multiple regions.

Who Supplies Adalimumab to India?

9 origin countries · Total import value: $227.6K

India imports adalimumab from 9 countries with a combined import value of $227.6K. The largest supplier is UNITED STATES ($167.7K, 27 shipments), followed by UNITED KINGDOM and GERMANY. All values are from Indian Customs (DGFT) import records.

Countries Supplying Adalimumab to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	UNITED STATES	$167.7K	27	73.7%
2	UNITED KINGDOM	$28.5K	5	12.5%
3	GERMANY	$18.4K	7	8.1%
4	CANADA	$6.0K	1	2.6%
5	BULGARIA	$5.3K	1	2.3%
6	NETHERLANDS	$849	1	0.4%
7	CHINA	$377	1	0.2%
8	SOUTH KOREA	$277	3	0.1%
9	IRELAND	$203	1	0.1%

UNITED STATES is the largest supplier of adalimumab to India, accounting for 73.7% of total import value. The top 5 origin countries — UNITED STATES, UNITED KINGDOM, GERMANY, CANADA, BULGARIA — together supply 99.3% of India's adalimumab imports. Click any country to see detailed supplier and buyer data for that import corridor.

Adalimumab — Export Intelligence Video

Visual overview of India's adalimumab import and export market — top suppliers, destinations, pricing, and trade routes

This video covers India's adalimumab pharmaceutical import and export market — $1.2M in total trade, 67 verified manufacturers, and 53 destination countries. Data sourced from Indian Customs (DGFT) shipment records.

Regulatory Landscape — Adalimumab

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, adalimumab is subject to the Biologics License Application (BLA) pathway, as it is a biologic product. The FDA's Orange Book provides comprehensive information on approved drug products, including adalimumab and its biosimilars. As of March 2026, several biosimilar versions of adalimumab have received FDA approval, enhancing market competition and accessibility. Notably, the approval of these biosimilars reflects the FDA's commitment to expanding treatment options for patients with autoimmune diseases.

Given the complexity of biologic products, the FDA imposes stringent requirements for the approval of biosimilars, including demonstrating similarity to the reference product in terms of safety, purity, and potency. The presence of 67 active Indian exporters underscores India's significant role in the global supply chain for adalimumab. However, Indian manufacturers aiming to enter the U.S. market must navigate the rigorous BLA process and adhere to the FDA's stringent regulatory standards.

2EU & UK Regulatory Framework

In the European Union, the European Medicines Agency (EMA) oversees the approval of medicinal products, including biosimilars like adalimumab. The EMA has granted marketing authorizations for several adalimumab biosimilars; however, some, such as Halimatoz, Kromeya, Cyltezo, and Solymbic, had their authorizations withdrawn between 2018 and 2020 at the request of the marketing authorization holders for commercial reasons. Despite these withdrawals, other biosimilars remain authorized and marketed within the EU.

The United Kingdom, following its departure from the EU, has established its own regulatory framework through the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA continues to assess and authorize biosimilars, including adalimumab, ensuring they meet the necessary standards for safety, efficacy, and quality.

Both the EMA and MHRA require compliance with Good Manufacturing Practice (GMP) standards, which are critical for ensuring product quality and patient safety. Indian exporters must demonstrate adherence to these standards to gain and maintain market access in the EU and UK.

3WHO Essential Medicines & Global Standards

The World Health Organization (WHO) includes adalimumab in its Model List of Essential Medicines, recognizing its importance in treating conditions like ankylosing spondylitis, Crohn's disease, juvenile idiopathic arthritis, and rheumatoid arthritis. The 2023 Model List also acknowledges therapeutic alternatives such as certolizumab pegol, etanercept, golimumab, and infliximab. (who.int)

Inclusion in the WHO Model List signifies the global health community's recognition of adalimumab's essential role in managing autoimmune diseases. This designation can influence national formularies and procurement decisions, potentially impacting export opportunities for Indian manufacturers.

4India Regulatory Classification

In India, adalimumab is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The Central Drugs Standard Control Organization (CDSCO) oversees the regulation of such drugs, ensuring their safety and efficacy.

The National Pharmaceutical Pricing Authority (NPPA) monitors and regulates the prices of essential medicines in India. While specific ceiling prices for adalimumab are subject to periodic revisions, the NPPA's role is crucial in ensuring affordability and accessibility.

For exports, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

5Patent & Exclusivity Status

The original patents for adalimumab have expired in several jurisdictions, leading to increased generic competition and the introduction of biosimilars. This shift has expanded market opportunities for Indian exporters, allowing them to supply biosimilar versions to various countries.

6Recent Industry Developments

In February 2025, the WHO highlighted the role of biosimilars in expanding access to essential biologic therapies, emphasizing the importance of regulatory frameworks to ensure their quality and efficacy. (who.int)

In April 2025, the WHO unveiled a global repository for National Essential Medicines Lists (nEMLs), providing a centralized platform for accessing information on essential medicines, including adalimumab. (who.int)

These developments underscore the evolving landscape of biosimilar regulation and the increasing emphasis on ensuring access to essential medicines globally.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Adalimumab

Retail & reference prices across 9 markets vs. India FOB export price of $111.11/unit

Global Price Benchmark for Adalimumab across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$2,500	USD	According to the FDA's Orange Book, Adalimumab is approved under various brand names, with pricing subject to market competition and insurance coverage.
United Kingdom	Approximately $455	GBP	The NHS Drug Tariff lists Adalimumab under its formulary, with prices negotiated to ensure cost-effectiveness for the healthcare system.
Germany	Approximately $1,320	EUR	The Federal Joint Committee (G-BA) oversees the pricing and reimbursement of pharmaceuticals, including Adalimumab, within the statutory health insurance system.

Supply Chain Risk Assessment — Adalimumab

API sourcing, concentration risk, storage requirements, and current alerts

MEDIUM RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, including the production of Adalimumab, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of India's API and KSM requirements are sourced from China, underscoring a significant dependency on Chinese suppliers. This reliance exposes the supply chain to vulnerabilities stemming from geopolitical tensions, trade disputes, and regulatory changes in China.

Recent disruptions have highlighted these risks. In September 2025, China implemented a price reduction of 40–50% on 41 APIs and KSMs, including critical components for antibiotics, aiming to undercut Indian manufacturers. Such aggressive pricing strategies can destabilize Indian API production, leading to potential shortages and increased costs for Adalimumab manufacturers.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five Indian exporters of Adalimumab account for 41.5% of total exports, with RELIANCE LIFE SCIENCES PRIVATE LIMITED alone contributing 28.3%. This concentration suggests a moderate risk, as disruptions affecting these key suppliers could significantly impact the global supply of Adalimumab.

To mitigate such risks, the Indian government has introduced the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API and KSM production. By November 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, reducing import dependence. While these initiatives are promising, their impact on Adalimumab's supply chain remains to be fully realized.

Access Complete Adalimumab Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 223 transactions across 53 markets.

Request Demo View Pricing

Frequently Asked Questions — Adalimumab Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top adalimumab exporters from India?

The leading adalimumab exporters from India are RELIANCE LIFE SCIENCES PRIVATE LIMITED, ZYDUS LIFESCIENCES LIMITED, CADILA HEALTHCARE LIMITED, and 7 others. RELIANCE LIFE SCIENCES PRIVATE LIMITED leads with 28.3% market share ($338.1K). The top 5 suppliers together control 41.5% of total export value.

What is the total export value of adalimumab from India?

The total export value of adalimumab from India is $1.2M, recorded across 223 shipments from 67 active exporters to 53 countries. The average shipment value is $5.3K.

Which countries import adalimumab from India?

India exports adalimumab to 53 countries. The top importing countries are VENEZUELA (27.9%), SRI LANKA (20.0%), NEPAL (10.9%), BANGLADESH (9.9%), UNITED ARAB EMIRATES (6.6%), which together account for 75.3% of total export value.

What is the HS code for adalimumab exports from India?

The primary HS code for adalimumab exports from India is 30021500. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Adalimumab

Adalimumab

Top Adalimumab Exporters from India

Top Countries Importing Adalimumab from India

Who Supplies Adalimumab to India?

Quick Facts

Related Biologics & Immunotherapy

Related Analysis

Need Details?

Adalimumab — Export Intelligence Video

Regulatory Landscape — Adalimumab

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Adalimumab

Supply Chain Risk Assessment — Adalimumab

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Adalimumab Trade Intelligence

Frequently Asked Questions — Adalimumab Exports from India

Who are the top adalimumab exporters from India?

What is the total export value of adalimumab from India?

Which countries import adalimumab from India?

What is the HS code for adalimumab exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of adalimumab exports from India?

Which ports handle adalimumab exports from India?

Why is India a leading exporter of adalimumab?

What certifications do Indian adalimumab exporters need?

How many buyers import adalimumab from India?

What is the market share of the top adalimumab exporter from India?

Analysis Methodology